Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Shares Issued (2022 - 2025)

Prime Medicine (PRME) has disclosed Shares Issued for 4 consecutive years, with $781000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued changed N/A year-over-year to $781000.0, compared with a TTM value of $781000.0 through Dec 2025, down 95.85%, and an annual FY2025 reading of $781000.0, down 95.85% over the prior year.
  • Shares Issued was $781000.0 for Q4 2025 at Prime Medicine, down from $17.6 million in the prior quarter.
  • Across five years, Shares Issued topped out at $17.6 million in Q2 2024 and bottomed at -$68000.0 in Q2 2023.
  • Average Shares Issued over 4 years is $2.8 million, with a median of $156000.0 recorded in 2022.
  • Peak annual rise in Shares Issued hit 25982.35% in 2024, while the deepest fall reached 1664.71% in 2024.
  • Year by year, Shares Issued stood at $156000.0 in 2022, then crashed by 143.59% to -$68000.0 in 2023, then soared by 25982.35% to $17.6 million in 2024, then tumbled by 95.56% to $781000.0 in 2025.
  • Business Quant data shows Shares Issued for PRME at $781000.0 in Q4 2025, $17.6 million in Q2 2024, and $1.2 million in Q1 2024.